Skip to main content

Advertisement

Table 1 Results of logistic regression model of KIR/HLA and HIV acquisition

From: Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

  HIV- (n = 155) HIV+ (n = 154) pa ORa 95 % CIa
  - + + % - + + %    
KIR loci
KIR2DL1 4 151 97.4 % 0 154 100.0 % 0.98 - -
KIR2DL2 45 110 71.0 % 46 107 69.9 % 0.89 1.04 0.63–1.71
 KIR2DL2/KIR2DL2   39 25.5 %   35 22.9 %    
 KIR2DL2/KIR2DL3   70 45.8 %   72 47.1 % 0.63 1.15 0.43–2.05
 KIR2DL3/KIR2DL3   44 28.8 %   46 30.1 % 0.83 1.07 0.32–2.00
KIR2DL3 40 114 74.0 % 35 118 77.1 % 0.61 1.15 0.68–1.94
KIR2DL4 3 152 98.1 % 0 154 100.0 % 0.98 - -
KIR2DL5 44 111 71.6 % 56 98 63.6 % 0.18 0.72 0.44–1.16
KIR3DL1 0 155 100.0 % 0 154 100.0 % - - -
 KIR3DL1/KIR3DL1   145 94.8 %   141 92.2 %    
 KIR3DL1/KIR3DS1   8 5.2 %   12 7.8 % 0.27 1.69 0.62-4.04
 KIR3DS1/KIR3DS1   0 0.0 %   0 0.0 % - - -
KIR3DS1 145 8 5.2 % 141 12 7.8 % 0.27 1.69 0.67–4.45
KIR3DL2 0 155 100.0 % 0 154 100.0 % - - -
KIR3DL3 2 153 98.7 % 0 154 100.0 % 0.98 - -
KIR2DS1 135 18 11.8 % 130 24 15.6 % 0.23 1.51 0.78–2.96
KIR2DS2 63 92 59.4 % 60 94 61.0 % 0.56 1.15 0.72–1.83
KIR2DS3 104 51 32.9 % 111 43 27.9 % 0.43 0.82 0.50–1.34
 KIR2DS3/KIR2DS3   29 25.9 %   24 24.2 %    
 KIR2DS3/KIR2DS5   22 19.6 %   19 19.2 % 0.77 1.13 0.49–2.60
 KIR2DS5/KIR2DS5   61 54.5 %   56 56.6 % 0.77 1.11 0.57–2.14
KIR2DS5 72 83 53.5 % 79 75 48.7 % 0.47 0.85 0.54–1.33
KIR2DS4b 2 153 98.7 % 1 153 99.4 % 0.63 1.80 0.17–39.03
197/.   23 20.2 %   11 19.0 %    
197/219   31 27.2 %   25 43.1 % 0.25 1.57 0.70–4.21
./219   60 52.6 %   22 37.9 % 0.55 1.56 0.32–1.87
KIR Haplotype
Bx 33 121 78.6 % 40 113 73.9 % 0.45 0.81 0.48–1.39
AA   33 21.4 %   40 26.1 %    
AB   77 50.0 %   78 51.0 % 0.65 0.88 0.50–1.55
BB   44 28.6 %   35 22.9 % 0.27 0.70 0.36–1.33
HLA Groups
Protective B alleles 122 33 21.3 % 128 26 16.9 % 0.33 0.75 0.42–1.33
Harmful B alleles 108 47 30.3 % 104 50 32.5 % 0.80 1.07 0.66–1.73
Bw4 109 46 29.7 % 103 51 33.1 % 0.50 1.18 0.73–1.92
Bw6 75 80 51.6 % 77 77 50.0 % 0.70 0.92 0.58–1.44
C1/C1   21 13.5 %   18 11.7 %    
C1/C2   68 43.9 %   73 47.4 % 0.76 1.35 0.65–2.81
C2/C2   66 42.6 %   63 40.9 % 0.70 1.18 0.56–2.52
KIR/HLA Ligand Pair
KIR2DL1_C2 33 122 78.7 % 25 129 83.8 % 0.22 1.44 0.81–2.59
KIR2DS1_C2 140 15 9.7 % 132 22 14.3 % 0.15 1.68 0.84–3.46
KIR2DL2_C1 90 65 41.9 % 92 62 40.3 % 0.77 0.93 0.59–1.47
KIR2DL3_C1 94 61 39.4 % 85 69 44.8 % 0.43 1.20 0.76–1.90
KIR3DL1_Bw4 109 46 29.7 % 103 51 33.1 % 0.50 1.18 0.73–1.92
KIR3DS1_Bw4 150 5 3.2 % 148 6 3.9 % 0.68 1.29 0.38–4.59
KIR2DS4_Cw04 128 27 17.4 % 128 26 16.9 % 0.86 1.04 0.57–1.91
KIR3DL2_A3A11 134 21 13.5 % 133 21 13.6 % 0.98 1.01 0.52–1.95
  1. Previous Presentations: A part of these data was presented at the International Immunogenetics and HLA Workshop 2012. Liverpool, UK, 28 May-3 June 2012
  2. a(adjusted for tenofovir gel use)
  3. bFor a subset (172/309, 56 %) KIR2DS4 alleles were genotyped where 197 denotes the common deletion variant of KIR2DS4 that has a 22 bp deletion in exon 5